• In early February 2026, Novo Nordisk filed a patent infringement lawsuit against Hims & Hers over its compounded semaglutide weight-loss products, following an FDA crackdown that also prompted Hims & Hers to abruptly halt its newly launched Compounded GLP-1 Pill.
• The clash not only raises serious questions about the safety and legality of compounded GLP-1 treatments, but also directly challenges Hims & Hers' efforts to expand its weight-loss franchise as a core growth driver.
• We’ll now examine how the Novo Nordisk lawsuit and regulatory scrutiny over compounded semaglutide could reshape Hims & Hers’ investment narrative.

Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Hims & Hers Health Investment Narrative Recap

To own Hims & Hers today, you need to believe its broader telehealth platform and diversified specialties can absorb shocks from its GLP‑1 business. The Novo Nordisk lawsuit and FDA scrutiny hit what had been a key near term growth driver in compounded semaglutide, while amplifying the biggest current risk: heavy reliance on weight loss for revenue momentum and investor sentiment. The immediate question is how quickly Hims & Hers can pivot demand back to approved and non‑GLP‑1 offerings.

The launch of the Hims & Hers Multi‑Cancer Test by Galleri is especially relevant here, because it highlights management’s push into preventative, subscription‑like services that sit outside contentious drug categories. While it will not offset GLP‑1 disruption overnight, it shows the business is not purely a weight loss story and could matter more if regulators and brand owners tighten the screws on compounded semaglutide.

Yet beneath the growth story, investors should be aware of how regulatory actions around compounded GLP‑1s could interact with…

Hims & Hers Health's narrative projects $3.3 billion revenue and $261.3 million earnings by 2028. This requires 18.3% yearly revenue growth and about a $67.7 million earnings increase from $193.6 million today.

Uncover how Hims & Hers Health's forecasts yield a $44.36 fair value, a 172% upside to its current price.

Exploring Other Perspectives

Before this legal shock, the most bearish analysts already expected slower growth, with revenue around US$3.1 billion and earnings near US$268.9 million by 2028, warning that tighter GLP‑1 regulation and pricing pressure could weigh far more heavily than the consensus narrative suggests.

Explore 55 other fair value estimates on Hims & Hers Health - why the stock might be worth just $28.00!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Hims & Hers Health research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Hims & Hers Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Hims & Hers Health's overall financial health at a glance.

Searching For A Fresh Perspective?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Find 55 companies with promising cash flow potential yet trading below their fair value.
• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.